Clinical trial
A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in…
NCT00418821 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00418821 |
|---|---|
| Title | A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants |
| Official title | A Multicenter, Multinational, Open-Label Study of the Effects of Aldurazyme® (Laronidase) Treatment on Lactation in Women With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Collaborators | BioMarin/Genzyme LLC Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie |
| Intervention type | Biological |
| Interventions | Laronidase |
| Enrollment | 2 |
| Start date | Oct 22, 2010 |
| Primary completion | Dec 21, 2022 |
| Completion | Dec 21, 2022 |
| First posted | Jan 5, 2007 |
| Last update posted | Feb 20, 2024 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: